四环生物(000518) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥100,507,371.73, an increase of 12.84% year-on-year [8]. - Net profit attributable to shareholders was -¥10,420,808.28, a decrease of 171.73% compared to the same period last year [8]. - Basic earnings per share were -¥0.0101, a decrease of 171.63% year-on-year [8]. - The weighted average return on net assets was -1.67%, down from -3.35% in the previous year [8]. - The company received government subsidies amounting to ¥1,282,389.09 during the reporting period [9]. Assets and Liabilities - Total assets at the end of the reporting period were ¥904,069,868.18, a decrease of 2.96% compared to the end of the previous year [8]. - Prepayments increased by 168.90% to ¥10,742,405.13 due to increased procurement prepayments by Beijing Sihuan [16]. - Other receivables decreased by 34.50% to ¥5,668,868.27 as the company recovered other receivables during the reporting period [16]. - Short-term borrowings decreased by 60.00% to ¥20,000,000.00, with the company repaying ¥50,000,000.00 of maturing loans [16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥38,066,832.40, an increase of 111.73% [8]. - Operating cash outflows decreased by 56.39% to ¥263,735,794.01, primarily due to reduced large-scale procurement expenditures [18]. - Investment activity cash inflows dropped by 99.90% to ¥252,685.26, with no significant investment activities during the reporting period [18]. - The company reported a 400.00% increase in cash used for debt repayment, totaling ¥50,000,000.00 [18]. - The company did not engage in any significant asset disposals during the reporting period, leading to a 100.00% decrease in cash received from such activities [18]. Shareholder Information - The company reported a total of 72,030 common shareholders at the end of the reporting period [12]. - The largest shareholder, Wang Hongming, holds 14.00% of the shares, totaling 144,138,394 shares [12]. Operational Changes - There were no significant changes in the company's strategy or new product developments reported during this quarter [15]. - There were no significant changes in the company's commitments or guarantees during the reporting period [19]. Expenses - Sales expenses increased by 44.02% to ¥152,762,643.95, indicating higher operational costs [16]. - Financial expenses rose by 90.26% to ¥2,124,233.91 due to increased loan interest expenses [16].